Abstract
Publications and patents relative to newly observed functions of β-(1,3)-D-glucans have notably increased in the last few years with the exploitation of their biological activities. The term β-(1,3)-D-glucans includes a very large number of polysaccharides from bacterial, fungal and vegetable sources. Their structures have a common backbone of β-(1,3) linked glucopyranosyl residues but the polysaccharidic chain can be β-(1,6) branched with glucose or integrate some β- (1,4) linked glucopyranosyl residues in the main chain. Except for the curdlan, a bacterial linear β-(1,3)-D-glucans, and for the scleroglucan produced by Sclerotium rolfsii, the main drawback limiting the development of these polysaccharides is the lack of efficient processes for their extraction and purification and their cost. However new applications in agronomy, foods, cosmetic and therapeutic could in a next future accentuate the effort of research for their development. So this review focuses on these β-(1,3)-D-glucans with the objective to detail the strategies employed for their extraction and the relation structure-functions identified when they induce biological activities.
Keywords: Polysaccharides, oligosaccharides, curdlan, glucan, biopolymer
Recent Patents on Biotechnology
Title: New Developments and Prospective Applications for β (1,3) Glucans
Volume: 1 Issue: 1
Author(s): Celine Laroche and Philippe Michaud
Affiliation:
Keywords: Polysaccharides, oligosaccharides, curdlan, glucan, biopolymer
Abstract: Publications and patents relative to newly observed functions of β-(1,3)-D-glucans have notably increased in the last few years with the exploitation of their biological activities. The term β-(1,3)-D-glucans includes a very large number of polysaccharides from bacterial, fungal and vegetable sources. Their structures have a common backbone of β-(1,3) linked glucopyranosyl residues but the polysaccharidic chain can be β-(1,6) branched with glucose or integrate some β- (1,4) linked glucopyranosyl residues in the main chain. Except for the curdlan, a bacterial linear β-(1,3)-D-glucans, and for the scleroglucan produced by Sclerotium rolfsii, the main drawback limiting the development of these polysaccharides is the lack of efficient processes for their extraction and purification and their cost. However new applications in agronomy, foods, cosmetic and therapeutic could in a next future accentuate the effort of research for their development. So this review focuses on these β-(1,3)-D-glucans with the objective to detail the strategies employed for their extraction and the relation structure-functions identified when they induce biological activities.
Export Options
About this article
Cite this article as:
Laroche Celine and Michaud Philippe, New Developments and Prospective Applications for β (1,3) Glucans, Recent Patents on Biotechnology 2007; 1 (1) . https://dx.doi.org/10.2174/187220807779813938
DOI https://dx.doi.org/10.2174/187220807779813938 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relaxin Receptors - New Drug Targets for Multiple Disease States
Current Drug Targets Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Hyperforin Analogues for Inhibition of 5-lipoxygenase
Medicinal Chemistry Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Targeting Drug-Resistant Prostate Cancer with Dual PI3K/mTOR Inhibition
Current Medicinal Chemistry Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Anticancer Agents Derived from Natural Cinnamic Acids
Anti-Cancer Agents in Medicinal Chemistry Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Current Pharmaceutical Biotechnology Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Safety Considerations Associated with Development and Clinical Application of Lentiviral Vector Systems for Gene Transfer
Current Genomics Toll-Like Receptor Signaling Mechanisms Involved in Dendritic Cell Activation: Potential Therapeutic Control of T Cell Polarization
Current Pharmaceutical Design Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Reviews on Recent Clinical Trials Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Predicting Drug Metabolism Induction In Silico
Current Topics in Medicinal Chemistry Current Status of Newer Carbapenems
Current Medicinal Chemistry